Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel
NASDAQ:ORKA

Oruka Therapeutics Q4 2025 Earnings Report

Oruka Therapeutics logo
$69.17 +0.22 (+0.31%)
As of 11:48 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Oruka Therapeutics EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.61
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Oruka Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oruka Therapeutics Announcement Details

Quarter
Q4 2025
Date
3/12/2026
Time
Before Market Opens
Conference Call Date
Thursday, March 12, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Oruka Therapeutics' Q1 2026 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q1 2026 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

Oruka Therapeutics' Q4 2025 Press ReleasePress Release
(8-K)
Oruka Therapeutics' Q4 2025 Annual reportAnnual report
(10-K)

Oruka Therapeutics Earnings Headlines

Halozyme Therapeutics, Inc.: Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon Technology
 |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68411498-halozyme-therapeutics-inc-halozyme-and-oruka-announce-global-collaboration-and-license-agreement-to-develop-orka-001-with-hypercon-technology-008.htm
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/halozyme-and-oruka-announce-global-collaboration-and-license-agreement-to-develop-orka-001-with-hypercon-technology-302763746.html
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 6 at 1:00 AM  |  Profits Run (Ad)
Oruka Therapeutics prices upsized $700M public offering at $72.50 per share
April 30, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/oruka-therapeutics-prices-upsized-700m-public-offering-at-7250-per-share/ar-AA21Yj2D
Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
April 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/oruka-therapeutics-orka-reports-positive-135736753.html
Stifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
April 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1610963/stifel-nicolaus-keeps-their-buy-rating-on-oruka-therapeutics-orka/
See More Oruka Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email.

About Oruka Therapeutics

Oruka Therapeutics (NASDAQ:ORKA) is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy. In addition to ONCT-01, Oruka’s pipeline includes multiple preclinical programs directed at key targets such as MDM2-p53 and MYC, reflecting a broad strategy to address unmet needs across various tumor types. The company’s research efforts extend to both monotherapy and combination therapy approaches to enhance anti‐tumor activity.

Headquartered in the United States, Oruka Therapeutics became a publicly traded company in 2022 and is listed on the NASDAQ under the symbol ORKA. The organization is led by a management team with extensive experience in peptide chemistry, oncology drug development and clinical operations. Oruka continues to advance its technology platform and pipeline toward the goal of delivering innovative cancer treatments to patients worldwide.

View Oruka Therapeutics Profile
Earnings Tools